JP2023520770A - 肺浮腫又は肺炎症を治療するための組成物及び方法 - Google Patents

肺浮腫又は肺炎症を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2023520770A
JP2023520770A JP2022558131A JP2022558131A JP2023520770A JP 2023520770 A JP2023520770 A JP 2023520770A JP 2022558131 A JP2022558131 A JP 2022558131A JP 2022558131 A JP2022558131 A JP 2022558131A JP 2023520770 A JP2023520770 A JP 2023520770A
Authority
JP
Japan
Prior art keywords
dose
lung
serum
hours
hyperoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520770A5 (https=
Inventor
エイチ．イングバー デイビッド
ピー．リッチ ティモシー
ジェイ．シューマッハー ロバード
Original Assignee
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リージェンツ オブ ザ ユニバーシティ オブ ミネソタ filed Critical リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Publication of JP2023520770A publication Critical patent/JP2023520770A/ja
Publication of JP2023520770A5 publication Critical patent/JP2023520770A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022558131A 2020-03-27 2021-03-26 肺浮腫又は肺炎症を治療するための組成物及び方法 Pending JP2023520770A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000939P 2020-03-27 2020-03-27
US63/000,939 2020-03-27
PCT/US2021/024345 WO2021195488A1 (en) 2020-03-27 2021-03-26 Compositions and methods for treating pulmonary edema or lung inflammation

Publications (2)

Publication Number Publication Date
JP2023520770A true JP2023520770A (ja) 2023-05-19
JP2023520770A5 JP2023520770A5 (https=) 2024-06-24

Family

ID=77892642

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558131A Pending JP2023520770A (ja) 2020-03-27 2021-03-26 肺浮腫又は肺炎症を治療するための組成物及び方法

Country Status (7)

Country Link
US (1) US12569459B2 (https=)
EP (1) EP4126104A4 (https=)
JP (1) JP2023520770A (https=)
CN (1) CN115551569A (https=)
CA (1) CA3177377A1 (https=)
MX (1) MX2022011821A (https=)
WO (1) WO2021195488A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025024778A1 (en) * 2023-07-27 2025-01-30 Regents Of The University Of Minnesota Medical treatment system and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148433A1 (en) * 2007-12-06 2009-06-11 Naidu Lp Metallo-protein and tocotrienol (mp-t3) compositions and uses thereof
US20160199309A1 (en) * 2009-06-17 2016-07-14 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20180030540A1 (en) * 2009-04-29 2018-02-01 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Classification of Thyroid Tissue
WO2019152659A1 (en) * 2018-01-31 2019-08-08 Regents Of The University Of Minnesota Compositions and methods for treating pulmonary edema or lung inflammation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716877B2 (en) 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US8304401B2 (en) 2008-09-02 2012-11-06 Trustees Of Dartmouth College Compositions and methods for decreasing type III deiodinase activity to modulate adiposity and blood glucose levels
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
EP3119768B1 (en) 2014-03-16 2019-07-31 Hadasit Medical Research Services And Development Ltd. 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer
US9913819B2 (en) 2014-06-12 2018-03-13 Yale University Methods of treating or preventing fibrotic lung diseases
CN107041879A (zh) 2017-04-01 2017-08-15 深圳市润佳通科技有限公司 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防肺部疾病的药物中的应用
WO2019178023A1 (en) 2018-03-12 2019-09-19 Yale University Methods of Treating or Preventing Acute Respiratory Distress Syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148433A1 (en) * 2007-12-06 2009-06-11 Naidu Lp Metallo-protein and tocotrienol (mp-t3) compositions and uses thereof
US20180030540A1 (en) * 2009-04-29 2018-02-01 Genomedx Biosciences, Inc. Systems and Methods for Expression-Based Classification of Thyroid Tissue
US20160199309A1 (en) * 2009-06-17 2016-07-14 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2019152659A1 (en) * 2018-01-31 2019-08-08 Regents Of The University Of Minnesota Compositions and methods for treating pulmonary edema or lung inflammation

Also Published As

Publication number Publication date
EP4126104A4 (en) 2024-04-17
US20230147865A1 (en) 2023-05-11
MX2022011821A (es) 2022-10-10
EP4126104A1 (en) 2023-02-08
CA3177377A1 (en) 2021-09-30
CN115551569A (zh) 2022-12-30
US12569459B2 (en) 2026-03-10
WO2021195488A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
US11883528B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
AU2018286571B2 (en) Liquid inhalation formulation comprising RPL554
HK1249415A1 (en) Liquid inhalation formulation comprising rpl554
US6702998B2 (en) Methods and devices for treating lung dysfunction
JP2012107047A (ja) 気管支感染症の治療法
Vadász et al. Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+, K+-ATPase
US5658881A (en) Method for topical inhibition of the metabolic activity of cytochrome P450
US20220265775A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
US12569459B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
JP7041961B2 (ja) ヒト嚢胞性線維症肺上皮における気道表面の生理機能の小分子介在性回復
HK40087339A (zh) 用於治疗肺水肿或肺炎的组合物和方法
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
HK40046684A (en) Compositions and methods for treating pulmonary edema or lung inflammation
EP4326231A1 (en) Compositions of interleukin-1 receptor antagonist
EP2547335A2 (en) Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
Kearns et al. 88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF)
Kappeler et al. Liposomal Cyclosporine A for Inhalation (L-CsA-i) to Treat Bronchiolitis Obliterans Syndrome: Novel Formulation and Drug-Specific Delivery System Improve Tolerability
HK40007474B (en) Liquid inhalation formulation comprising rpl554
WO2021211006A1 (en) Inhaled hexapeptide for treating interleukin-6 related respiratory diseases
WO2022005321A1 (en) Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
Keller et al. 91 Medical rationale for nebulisation of a novel high-concentration (100mg/mL) aqueous azithromycin inhalation solution
Ito et al. 90 Inhibitory effects of RV1088, a novel narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis
Ito et al. 89 Superior effects of RV568, a narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis
HK1233919B (en) Liquid inhalation formulation comprising rpl554
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260409